Research programme: tacrolimus analogues - Kosan Biosciences

Drug Profile

Research programme: tacrolimus analogues - Kosan Biosciences

Latest Information Update: 10 Nov 2003

Price : $50

At a glance

  • Originator Kosan Biosciences
  • Class
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Transplant rejection

Most Recent Events

  • 10 Nov 2003 Discontinued - Preclinical for Transplant rejection in USA (unspecified route)
  • 10 Nov 2003 This programme is available for licensing (
  • 12 Jul 2000 New profile
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top